TABLE 1

Bortezomib Induces G₂–M Phase Arrest in ATC Cell Lines

		Phase
Cell line	Concentration (nM)	G₁	S	G₂–M
SW1736
12 h	0	47.97 ± 0.78	36.77 ± 1.07	15.20 ± 0.29
	100	38.28 ± 1.43	32.90 ± 1.45	28.51 ± 0.42
24 h	0	42.83 ± 1.5	34.77 ± 0.35	22.31 ± 1.02
	100	34.94 ± 2.02	38.68 ± 3.35	26.38 ± 1.33
48 h	0	50.16 ± 1.42	31.44 ± 1.4	18.40 ± 0.02
	100	48.25 ± 0.78	23.42 ± 0.75	28.33 ± 0.03
C643
12 h	0	49.57 ± 0.03	31.25 ± 0.21	19.17 ± 0.18
	100	27.36 ± 0.13	33.70 ± 1.29	38.94 ± 1.42
24 h	0	35.90 ± 1.06	40.71 ± 0.59	23.39 ± 1.66
	100	22.14 ± 0.03	33.97 ± 0.34	43.89 ± 0.37
48 h	0	58.27 ± 1.94	29.32 ± 0.39	12.41 ± 1.55
	100	46.09 ± 0.72	27.50 ± 1.33	26.41 ± 0.35

Cell cycle analysis of SW1736 and C643 cells incubated without (0 nM) or with bortezomib (100 nM) for indicated times was performed using fluorescence-activated cell sorting analysis. Data represent percentage of cells in G₁, S, and G₂–M phases, indicated as mean values of triplicate samples and SD.